Study Title: A Randomized, Phase 2, Open-label Study of TransCon IL-2 B/y Monotherapy, TransCon IL-2 B/y in Combination with TransCon TLR7/8 Agonist, TransCon TLR7/8 Agonist in Combination with Pembrolizumab, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
For more information about the trial above please contact the study team: